Literature DB >> 14623357

The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders.

Mario van der Stelt1, Vincenzo Di Marzo.   

Abstract

To date, N-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol are the best studied endocannabinoids and are thought to act as retrograde messengers in the central nervous system (CNS). By activating presynaptic cannabinoid CB1 receptors, they can reduce glutamate release in dorsal and ventral striatum (nucleus accumbens) and alter synaptic plasticity, thereby modulating neurotransmission in the basal ganglia and in the mesolimbic reward system. In this review, we will focus on the role of the endocannabinoid system within these neuronal pathways and describe its effect on dopaminergic transmission and vice versa. The endocannabinoid system is unlikely to directly affect dopamine release, but can modify dopamine transmission trough trans-synaptic mechanisms, involving gamma-aminobutyric acid (GABA)-ergic and glutamatergic synapses, as well as by converging signal transduction cascades of the cannabinoid and dopamine receptors. The dopamine and endocannabinoid systems exert a mutual control on each other. Cannabinergic signalling may lead to release of dopamine, which can act via dopamine D1-like receptors as a negative feedback mechanism to counteract the effects of activation of the cannabinoid CB1 receptor. On the other hand, dopaminergic signalling via dopamine D2-like receptors may lead to up-regulation of cannabinergic signalling, which is likely to represent a negative feedback on dopaminergic signalling. The consequences of these interactions become evident in pathological conditions in which one of the two systems is likely to be malfunctioning. We will discuss neurological and psychiatric disorders such as Parkinson's and Huntington's disease, drug addiction and schizophrenia. Furthermore, the possible role of the endocannabinoid system in disorders not necessarily depending on the dopaminergic system, such as eating disorders and anxiety, will be described.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14623357     DOI: 10.1016/j.ejphar.2003.08.101

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  78 in total

1.  Effects of overnight fasting on working memory-related brain network: an fMRI study.

Authors:  Natalia Chechko; Sebastian Vocke; Ute Habel; Timur Toygar; Lisa Kuckartz; Mark Berthold-Losleben; Zacharias G Laoutidis; Stelios Orfanos; Annette Wassenberg; Wölfram Karges; Frank Schneider; Nils Kohn
Journal:  Hum Brain Mapp       Date:  2014-11-12       Impact factor: 5.038

2.  Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex.

Authors:  Chiayu Q Chiu; Nagore Puente; Pedro Grandes; Pablo E Castillo
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

Review 3.  Evidence for the use of cannabinoids in Parkinson's disease.

Authors:  Carsten Buhmann; Tina Mainka; Georg Ebersbach; Florin Gandor
Journal:  J Neural Transm (Vienna)       Date:  2019-05-27       Impact factor: 3.575

4.  Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of D(2)-induced formation of anandamide.

Authors:  Marcello Solinas; Gianluigi Tanda; Carrie E Wertheim; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2010-02-24       Impact factor: 4.530

5.  AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Authors:  Mark D Black; Rachel J Stevens; Nancy Rogacki; Robert E Featherstone; Yaw Senyah; Odessa Giardino; Beth Borowsky; Jeanne Stemmelin; Caroline Cohen; Philippe Pichat; Michal Arad; Segev Barak; Amaya De Levie; Ina Weiner; Guy Griebel; Geoffrey B Varty
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

Review 6.  Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.

Authors:  L Lyon; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2011-11-10       Impact factor: 4.530

7.  Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H2O2, and KATP channels.

Authors:  Zsuzsanna Sidló; Patricia H Reggio; Margaret E Rice
Journal:  Neurochem Int       Date:  2007-07-22       Impact factor: 3.921

8.  Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol.

Authors:  Marina Rubio; Douglas McHugh; Javier Fernández-Ruiz; Heather Bradshaw; J Michael Walker
Journal:  Neurosci Lett       Date:  2007-06-02       Impact factor: 3.046

9.  Cannabinoid CB1 /CB2 receptor agonists attenuate hyperactivity and body weight loss in a rat model of activity-based anorexia.

Authors:  Maria Scherma; Valentina Satta; Roberto Collu; Maria Francesca Boi; Paolo Usai; Walter Fratta; Paola Fadda
Journal:  Br J Pharmacol       Date:  2017-07-11       Impact factor: 8.739

10.  CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat.

Authors:  M Sabrina Spano; Liana Fattore; Gregorio Cossu; Serena Deiana; Paola Fadda; Walter Fratta
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.